Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Randomized Controlled Trial"
journalStr:"The Lancet. Oncology"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Randomized+Controlled+Trial%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Randomized+Controlled+Trial%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Randomized+Controlled+Trial%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Oncology%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
PubPharm (558)
1
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER) : survival endpoints at 5 years in an open-label, randomised, phase 3 study
enthalten in:
The Lancet. Oncology
| 2024
von
Pfister, C.
|
Gravis, G.
|
Flechon, A.
| +53
Wird geladen...
2
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours : a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2024
von
Bajpai, J.
|
Kapu, V.
|
Rath, S.
| +16
Wird geladen...
3
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585) : an interim analysis of the multicentre, double-blind, randomised phase 3 study
enthalten in:
The Lancet. Oncology
| 2024
von
Shitara, K.
|
Rha, S.
|
Wyrwicz, L.
| +22
Wird geladen...
4
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis results from a randomised, controlled, phase 3 study
enthalten in:
The Lancet. Oncology
| 2024
von
Grande, E.
|
Arranz, J.
|
De Santis, M.
| +20
Wird geladen...
5
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130) : final overall survival analysis from a randomised, controlled, phase 3 study
enthalten in:
The Lancet. Oncology
| 2024
von
Bamias, A.
|
Davis, I.
|
Galsky, M.
| +21
Wird geladen...
6
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) : a randomised, double-blind, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2023
von
Llovet, J.
|
Kudo, M.
|
Merle, P.
| +123
ErratumIn: Lancet Oncol. 2024 Apr;25(4):e137. - PMID 38547896
Wird geladen...
7
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA) : a randomised, double-blind, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2023
von
Monk, B.
|
Toita, T.
|
Wu, X.
| +26
Wird geladen...
8
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW) : 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
enthalten in:
The Lancet. Oncology
| 2023
von
Niemann, C.
|
Munir, T.
|
Moreno, C.
| +21
Wird geladen...
9
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19) : quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
enthalten in:
The Lancet. Oncology
| 2023
von
Velikova, G.
|
Morden, J.
|
Haviland, J.
| +15
ErratumIn: Lancet Oncol. 2023 Dec;24(12):e459. - PMID 38040001
Wird geladen...
10
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India : a randomised, active-controlled, multicentre, phase 2/3 trial
enthalten in:
The Lancet. Oncology
| 2023
von
Sharma, H.
|
Parekh, S.
|
Pujari, P.
| +24
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[56]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Randomized Controlled Trial
Filter aufheben
Zeitschrift: The Lancet. Oncology
Medienart
558
Aufsätze
548
E-Artikel
548
E-Ressourcen
10
Gedruckte Aufsätze
Zeitschriftentitel
The Lancet. Oncology
Thema
558
Clinical Trial, Phase III
Randomized Controlled Trial
547
Journal Article
449
Research Support, Non-U.S. Gov't
401
Multicenter Study
212
Comparative Study
101
Antibodies, Monoclonal, Humanized
86
EC 2.7.10.1
77
Antineoplastic Agents
63
Cisplatin
63
Q20Q21Q62J
58
Fluorouracil
58
U3P01618RT
56
Receptor, ErbB-2
50
Taxoids
48
15H5577CQD
48
Docetaxel
46
P88XT4IS4D
46
Paclitaxel
43
Protein Kinase Inhibitors
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
143
2020-
393
2010-2019
22
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
558
Englisch
Haven't found what you're looking for?
Wird geladen...